MPS II

MPS II

References in periodicals archive ?
Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome).
Mukopolisakkaridoz Tip II (MPS II) veya Hunter sendromu, ilk kez 1917 yilinda tanimlanan, X'e bagli resesif gecis gosteren, nadir gorulen bir lizozomal depo hastaligidir.
In vivo genome editing programs: Sangamo today also provided an update on its in vivo genome editing programs: SB-913 (mucopolysaccharidosis type II, or MPS II), SB-318 (MPS I), and SB-FIX (hemophilia B).
ZFN technology is an engineerable gene editing platform that is currently being evaluated in clinical trials for Mucopolysaccharidosis Type I, MPS II, hemophilia B, beta thalassemia and sickle cell disease.
Hunter Syndrome (MPS II) is a rare genetic disease which causes progressive damage and that affects less than 500 boys in the United States.
(NASDAQ : SGMO) reported 16 week reductions in urinary glycosaminoglycans, a key biomarker of Mucopolysaccharidosis Type II (MPS II) disease pathophysiology, in Cohort 2 of the Phase 1/2 CHAMPIONS Study evaluating SB-913.
M2 EQUITYBITES-May 3, 2018-REGENXBIO wins US FDA's Fast Track Designation for RGX-121 for initiation of Phase I/II clinical trial in MPS II pediatric patients
Mucopolysaccharidosis Type II (MPS II, Hunter syndrome, OMIM 309900) is one of the seven types of MPS I, II, III, IV, VI, VII, IX.
25 January 2018 - UK-based technology group Elektron Technology plc's (AIM: EKT) Elektron Eye Technology business has purchased the patent of the MPS II macular pigment screening device for the sum of GBP 220,000 (USD 314,320), the group said.
Hunter syndrome (mucopolysaccharidosis type II (MPS II)) is a lysosomal disease characterized by deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S).
On Monday, in a medical first, Brian Madeux received an experimental in-body gene-editing treatment intended to cure him of Mucopolysaccharidoses II, known as MPS II or Hunter syndrome, a rare disorder that causes progressive damage to the body's cells.
Therefore, MPs II and III are superior to MP I in the design of a wideband antenna.